Dimethylarginines as risk markers of atherosclerosis and chronic kidney disease in children with nephrotic syndrome.

Autor:	Hyla-Klekot L; Chorzow Center of Pediatrics and Oncology, Chorzów, Poland., Bryniarski P; Department of Urology, Medical University of Silesia, Zabrze, Poland., Pulcer B; Chorzow Center of Pediatrics and Oncology, Chorzów, Poland., Ziora K; Department and Clinic of Pediatrics, Medical University of Silesia, Zabrze, Poland., Paradysz A; Department of Urology, Medical University of Silesia, Zabrze, Poland.
Jazyk:	angličtina
Zdroj:	Advances in clinical and experimental medicine : official organ Wroclaw Medical University [Adv Clin Exp Med] 2015 Mar-Apr; Vol. 24 (2), pp. 307-14.
DOI:	10.17219/acem/40465
Abstrakt:	Background: Nephrotic syndrome in children is commonly associated with dyslipidemia, which is considered a risk factor for endothelial dysfunction and atherosclerosis. Recently new markers of endothelial dysfunction, such as asymmetric dimethylarginine (ADMA), have gained importance. Another L-arginine derivative--symmetric dimethylarginine (SDMA)--may reflect the glomerular filtration rate (GFR). Objectives: The main aim of this study was to assess ADMA as a marker of atherosclerosis. Secondly, SDMA was examined for GFR assessment. Material and Methods: The study involved 32 children with nephrotic syndrome. Several parameters were examined in the remission and relapse phases of nephrotic syndrome, including ADMA, SDMA, cholesterol, triglycerides and GFR. Results: In the relapse phase there was a negative correlation between ADMA and lipids (cholesterol and triglycerides). In both phases SDMA was negatively correlated with GFR. Conclusions: The role of ADMA as a marker for endothelial dysfunction is not significant. SDMA may be utilized to monitor GFR in children with nephrotic syndrome.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu